DEF 14A: Cytek Biosciences Announces 2024 Annual Meeting of Stockholders

Cytek Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, executive compensation, and the ratification of its independent accounting firm.

Summary

• Cytek Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, at 11:00 a.m. Pacific Time.
• Stockholders will vote on three proposals: electing two Class III directors (Wenbin Jiang, Ph.D. and Michael Holder) for a three-year term expiring in 2027, providing an advisory vote on executive compensation for 2023, and ratifying the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for the Annual Meeting is April 8, 2024.
• The proxy materials, including the proxy statement and the Annual Report on Form 10-K for the year ended December 31, 2023, were distributed on or about April 25, 2024.
• Stockholders can vote in advance by proxy over the telephone or the internet.
• The Board of Directors recommends voting FOR the election of the director nominees, FOR the approval of executive compensation, and FOR the ratification of the selection of Deloitte & Touche LLP.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for the annual meeting. The recommendations to vote FOR all proposals suggest a positive outlook from the board's perspective.

Positives

• The Board is recommending votes FOR all proposals, indicating confidence in the nominees and the selected accounting firm.
• Stockholders have multiple avenues to vote, including online, by phone, or by mail, ensuring broad participation.
• The company provides detailed information on how to access the meeting, submit questions, and obtain technical assistance.

Negatives

• Gisele Dion will no longer be on the board following the expiration of her term at the Annual Meeting.

Risks

• If stockholders fail to ratify the selection of Deloitte & Touche LLP, the Audit Committee will reconsider whether or not to retain that firm.
• The advisory vote on executive compensation is non-binding, meaning the Board is not obligated to act on the results, although they will consider stockholder concerns.
• Participation in the virtual meeting is limited due to the capacity of the host platform and access to the meeting will be accepted on a first come, first served basis.

Future Outlook

The document does not contain specific forward-looking statements about financial performance, but it outlines the company's ongoing corporate governance practices and compensation strategies.

Management Comments

• The Board believes that the current board leadership structure, coupled with a strong emphasis on board independence, provides effective independent oversight of management while allowing the Board and management to benefit from Dr. Jiangs executive leadership and operational experience, including familiarity with our business as a founder and Chief Executive Officer.
• Our Board believes that its independence and oversight of management is maintained effectively through this leadership structure, including the role and responsibilities of the lead independent director, the composition of the Board and sound corporate governance policies and practices.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including annual meetings, proxy statements, and disclosures related to executive compensation and related party transactions. The peer group analysis for executive compensation aligns with industry norms for benchmarking compensation levels.

Comparison to Industry Standards

• The company benchmarks executive compensation against a peer group of life sciences and medical device companies with revenues between $75 million and $500 million and market capitalization between $600 million and $6 billion.
• Peer group companies include 10X Genomics, Inc., Codexis, Inc., NeoGenomics, Inc., Accuray Incorporated, Enzo Biochem, Inc., Nevro Corp., Adaptive Biotechnologies Corporation, Standard BioTools Inc., Pacific Biosciences of California, Inc., AngioDynamics, Inc., Harvard Bioscience, Inc., Quanterix Corporation, AtriCure, Inc., Inotiv, Inc., Twist Bioscience Corporation, Axonics, Inc., Invitae Corporation, Veracyte, Inc., Berkeley Lights, Inc., and NanoString Technologies, Inc.
• The company's compensation consultant, Meridian Compensation Partners, LLC, reviewed executive compensation data of publicly-traded companies in the life sciences/medical device industries to identify appropriate market reference points for gathering compensation data.

Management Changes

Corporate Governance

Related Party Transactions

• The company is party to an Amended and Restated Investors Rights Agreement (IRA) with certain holders of its capital stock, including the holders of more than 5% of its outstanding capital stock, such as entities affiliated with HHLR Advisors, Ltd. and entities affiliated with RA Capital Management.
• The company has entered into an indemnification agreement with each of its directors and executive officers, which requires the company to indemnify them.

Stakeholder Impact

• Shareholders are asked to vote on key decisions regarding the company's direction and governance.
• Executive officers' compensation is tied to company performance, aligning their interests with those of shareholders.
• The selection of an independent accounting firm ensures the integrity of financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 5, 2024, and announce the voting results.
• The Board and its committees will continue to oversee corporate governance and compensation practices.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Deloitte & Touche LLP, Corporate Governance, Voting